Transluminal Technologies
Transluminal Technologies: Innovating cardiovascular devices for swift patient recovery post-surgery.
Founded
2008Transluminal Technologies: Innovating cardiovascular devices for swift patient recovery post-surgery.
Transluminal Technologies, founded with a mission to innovate in the field of interventional cardiovascular medical devices, focuses on developing advanced solutions to improve patient outcomes post-surgery. Their flagship product, the velox CD™, is the world's first bioabsorbable magnesium alloy closure device designed to achieve immediate hemostasis and facilitate rapid patient recovery by sealing arteriotomies and naturally absorbing over time. The company primarily targets the cardiovascular surgery market, aiming to enhance the efficiency and safety of vascular closure procedures.
Notable affiliated individuals and investors include key figures in the medical device industry, although specific names are not publicly disclosed. Transluminal Technologies has achieved significant milestones, including the development and successful implementation of their innovative velox CD™ device. The impact of their technology is profound, offering a safer, faster, and more reliable method for vascular closure, which translates to improved recovery times and outcomes for patients undergoing cardiovascular surgeries.
Companies similar to Transluminal Technologies include CloSys, eLum Technologies, Venock and Magnesium Development Company.
Transluminal Technologies was founded in 2008.
Transluminal Technologies' headquarters is located in Syracuse, NY, US.
Transluminal Technologies' most recent funding round was for $1.5M (USD) in May 2015.
As of May 21, 2015, Transluminal Technologies has disclosed funding of $3M (USD). Undisclosed round amounts are excluded.
Transluminal Technologies has 30 employees as of Feb 5, 2024.
